Alik Farber, MD
Boston University Chobanian & Avedisian School of Medicine
Dept of Surgery
Vascular and Endovascular Surgery

MD, Harvard Medical School

Dr. Farber is a graduate of Brown University and obtained his medical degree from Harvard Medical School. He completed a residency in general surgery at Massachusetts General Hospital; a vascular surgery fellowship at Dartmouth-Hitchcock Medical Center; and an endovascular surgery fellowship at the Southern Illinois School of Medicine. In addition to his role as Division Chief of Vascular and Endovascular Surgery, Dr. Farber is also Medical Director of BMC’s Catheterization and Angiography Laboratories and Co-Director of BMC’s Vascular Non-invasive Laboratory as well as Associate Chair for Clinical Operations in the Department of Surgery. He is a fellow in the American College of Surgeons and is a member of the American Board of Surgery. He is a member of many national and regional medical and surgical societies, including the Society for Vascular Surgery, where he was elected to distinguished fellow status in 2013, the Society of University Surgeons, the Western Vascular Surgery Society, the New England Society for Vascular Surgery, the International Society for Endovascular Surgery, and the Society for Clinical Vascular Surgery. Dr. Farber has served as a principal investigator in a number of clinical trials and is currently a National Co-Chair of the BEST-CLI Trial (Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia), a $25 million grant awarded by the National Institutes of Health (NIH), to conduct a four-year, randomized clinical trial comparing traditional bypass surgery with the less invasive alternative of endovascular treatment for patients with critical limb ischemia (CLI). He has written and published many articles about vascular and endovascular surgery, has served as a moderator for various vascular meetings, and developed a formal education program in vascular surgery while at Cedar-Sinai Medical Center in Los Angeles, CA, which resulted in the Golden Apple Teaching Award for teaching and mentoring residents. Since his arrival at BMC, Dr. Farber has made it his goal and mission to foster continued clinical excellence and academic productivity. He is currently the director of a fourth year medical school elective (BMC Surgery Bootcamp) which is designed to prepare medical students who are going into surgical internship.

Section Chief
Boston University Chobanian & Avedisian School of Medicine
Vascular and Endovascular Surgery

Boston University Chobanian & Avedisian School of Medicine
Vascular & Interventional

Boston University
Evans Center for Interdisciplinary Biomedical Research

A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols
05/01/2012 - 12/31/2015 (PI)
Grifols Inc.

A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm^2 to <= 36 cm^2
10/15/2013 - 08/30/2015 (PI)
HealthPoint Limited

A Non-Interventional Safety Study Providing 12 Months Follow-Up from First Exposure to HP802-247 in Subjects with Venous Leg Ulcer
05/01/2012 - 04/30/2015 (PI)
HealthPoint Limited

Observational Study of Tissue Plasminogen Activator Used for Catheter Directed Thrombolysis in Patients with Acute Lower Extremety Native Artery or Bypass Graft Occlusion
01/27/2014 - 01/26/2015 (PI)
Grifols Inc.

A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers
05/01/2012 - 04/30/2014 (PI)
HealthPoint Limited

Vital Access Venous Window Needle Guide for salvage of AV Fistulae (SAVE) Trial
08/15/2012 - 08/14/2013 (PI)
Vital Access Corp

IN-BALANCE VLU (Inflammation, Bacteria, and Angiogenesis effects in launching venous leg ulcer healing: a clinical evaluation)
08/01/2012 - 07/31/2013 (PI)
Celleration, Inc.

A Phase 2 randomized open label study to evaluate the effects of different intra-thrombus infusion regiments of plasmin humun compared to placebo
08/01/2011 - 07/31/2012 (PI)
Talecris Pharmaceuticals

A Phase 2 randomized open label study to evaluate the effects of different intra-thrombus infusion regiments of plasmin humun compared to placebo
08/01/2011 - 07/31/2012 (PI)
Talecris Pharmaceuticals

A Phase II Randomized, Double Blind, Placebo Controlled Dose Finding Study Investigating the Efficacy of HP802-247 in Venous Leg Ulcers
08/01/2009 - 12/31/2011 (PI)
HealthPoint Limited

Showing 10 of 16 results. Show All Results

09/14/2021 - 09/14/2024 (PI)
Novo Nordisk

Natural Progression of High-Risk Chronic Limb-Threatening Ischemia. The CLariTI Study.
03/25/2021 - 03/25/2024 (PI)
LimFlow Inc

A multicenter retrospective observational study to evaluate primary patency of arteriovenous fistulae 6 months post-surgery.
11/23/2020 - 11/23/2023 (PI)
Laminate Medical Technologies Inc.

A comparative evaluation of a marine polysaccharide dressing and a carboxymethylcellulose dressing on subjects with lower extremity venous ulcerss
10/14/2020 - 10/14/2023 (PI)
Medline Industries LLC

A Pivotal Study to Investigate the Safety and Effectiveness of the Limflow System for the…
12/11/2019 - 12/11/2022 (PI)
LimFlow Inc

A multicenter, prospective, randomized, placebo controlled, double blind study performed to…
09/24/2019 - 09/23/2022 (PI)
MediWound LTD.

A multi-center prospective study to evaluate the safety and effectiveness of the VasQ external suppo
11/01/2017 - 05/01/2022 (PI)
Laminate Medical Technologies Inc.

09/17/2013 - 03/31/2022 (PI)
Brigham & Women's NIH-NHLBI

Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration..
08/06/2018 - 06/01/2019 (PI)
Ilkos Therapeutic Inc

06/19/2017 - 06/01/2019 (PI)
Boston Scientific Corporation

Showing 10 of 16 results. Show All Results


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Farber A. Modern Treatment of Asymptomatic Carotid Stenosis-The Importance of Both Medical Therapy and Carotid Endarterectomy. JAMA Surg. 2022 Aug 01; 157(8):653-654. PMID: 35675059
  2. Levin SR, Farber A, King EG, Giles KA, Eslami MH, Patel VI, Hicks CW, Rybin D, Siracuse JJ. Female Sex is Associated with More Reinterventions after Endovascular and Open Interventions for Intermittent Claudication. Ann Vasc Surg. 2022 Oct; 86:85-93.View Related Profiles. PMID: 35809741; PMCID: PMC9846811; DOI: 10.1016/j.avsg.2022.05.036;
  3. Levin SR, King EG, Farber A, Cheng TW, Rybin D, Siracuse JJ. Unplanned Shunting Is Associated with Higher Stroke Risk after Eversion Carotid Endarterectomy. Ann Vasc Surg. 2022 Nov; 87:362-368.View Related Profiles. PMID: 35803457
  4. Powell RJ, Choudhry N, Conte M, Cziraky M, Giles K, Hamza T, Menard M, Rosenfeld K, Rowe V, Siracuse JJ, Strong M, Van Over M, Villarreal M, White C, Farber A. Factors associated with lower preoperative quality of life in patients with chronic limb-threatening ischemia in the BEST-CLI trial. J Vasc Surg. 2022 Dec; 76(6):1642-1650.View Related Profiles. PMID: 35714891
  5. Cheng TW, Farber A, King EG, Levin SR, Arinze N, Malas MB, Eslami MH, Garg K, Rybin D, Siracuse JJ. Access site complications are uncommon with vascular closure devices or manual compression after lower extremity revascularization. J Vasc Surg. 2022 Sep; 76(3):788-796.e2.View Related Profiles. PMID: 35618194
  6. Farber A. Surgery appears to outperform endovascular therapy for popliteal artery aneurysms; however, the real answer as to which treatment strategy works best and for whom remains elusive. J Vasc Surg. 2022 May; 75(5):1718-1719. PMID: 35461678
  7. Mathlouthi A, Elsayed N, Al-Nouri O, Farber A, Malas MB. Outcomes of Endovascular-First Versus Bypass-First Approach for Patients With Chronic Limb-Threatening Ischemia Using a Medicare-Linked Database. Ann Vasc Surg. 2022 Sep; 85:119-124. PMID: 35398193
  8. Arinze NV, Yin W, Lotfollahzadeh S, Napoleon MA, Richards S, Walker JA, Belghasem M, Ravid JD, Hassan Kamel M, Whelan SA, Lee N, Siracuse JJ, Anderson S, Farber A, Sherr D, Francis J, Hamburg NM, Rahimi N, Chitalia VC. Tryptophan metabolites suppress the Wnt pathway and promote adverse limb events in chronic kidney disease. J Clin Invest. 2022 01 04; 132(1).View Related Profiles. PMID: 34752422; PMCID: PMC8718145; DOI: 10.1172/JCI142260;
  9. Levin SR, Farber A, King EG, Beck AW, Osborne NH, DeMartino RR, Cheng TW, Rybin D, Siracuse JJ. Outcomes of axillofemoral bypass for intermittent claudication. J Vasc Surg. 2022 May; 75(5):1687-1694.e4.View Related Profiles. PMID: 34954271
  10. Levin SR, Carlson SJ, Farber A, Kalish JA, King EG, Martin MC, McPhee JT, Patel VI, Rybin D, Siracuse JJ. Percutaneous radial artery access for peripheral vascular interventions is a safe alternative for upper extremity access. J Vasc Surg. 2022 Jul; 76(1):174-179.e2.View Related Profiles. PMID: 34954273
Showing 10 of 314 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 313 publications over 24 distinct years, with a maximum of 41 publications in 2016


Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
Contact for Mentoring:

75 E. Newton St Collamore Building
Boston MA 02118
Google Map

Farber's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department